During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

[7] Renal function was assessed in every clinic visit, on days 1, 4, 8, and 11 of a 21-day cycle, or more frequently if indicated. Response of myeloma to treatment was defined as ≥ 50% decrease ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

BeiGene (NASDAQ:BGNE – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. Several ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

at 09:22 Kidneyhood.org Publishes "The Evidence-Based Guide to Kidney and Renal Diets": The First Comprehensive ... and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in ...

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Currently, CAR-T therapies have been shown to be effective for certain blood cancers, including lymphomas, leukaemia, and multiple myeloma but the applications ... 110 More People With Thyroid, Liver, ...